Nanotechnology-Based Treatment for Ophthalmic Diseases.

Area of Science:

• Ophthalmology
• Nanomedicine
• Drug Delivery

Background:

• Eye diseases cause significant vision impairment and blindness globally.
• Traditional drug delivery methods face challenges due to the eye's physiological barriers, leading to low bioavailability and poor patient compliance.
• Nanotechnology presents a promising approach to overcome these limitations in ophthalmic drug delivery.

Purpose of the Study:

• To review recent advancements in nanotechnology for treating ophthalmic diseases.
• To detail various nanocarrier systems and their potential for ocular applications.
• To explore the application of nanomedicine in anterior and posterior segment eye diseases, including cancer and gene therapy.

Main Methods:

• Review of current literature on nanotechnology in ophthalmology.
• Categorization and analysis of primary nanocarrier systems (lipid, polymeric, carbon-based, metallic).
• Examination of nanomedicine applications for specific ocular conditions and emerging therapies.

Main Results:

• Nanoparticles enhance corneal retention, barrier penetration, targeted delivery, and controlled release of drugs.
• Nanotechnology shows potential in treating cataracts, dry eye, inflammatory conditions, age-related macular degeneration, diabetic retinopathy, and ocular tumors.
• Emerging applications include ocular tissue regeneration and retinal gene therapy.

Conclusions:

• Nanotechnology offers significant potential to improve the efficacy and safety of treatments for a wide range of eye diseases.
• Addressing challenges in clinical translation, such as standardization and regulatory approval, is crucial for the widespread adoption of nanomedicine in ophthalmology.
• Future developments in nanomedicine hold promise for revolutionizing eye care and vision restoration.